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ABSTRACT
Background Dynamic computed tomography (CT) 
angiography is useful for evaluating of hepatic vascular-
ity. Although vasodilators increase hepatic blood flow, 
the utility of dynamic CT with vasodilators is unclear. 
Here we investigated the utility and safety of dynamic 
CT with vasodilators.
Methods A prospective case-control radiographic 
evaluation using abdominal dynamic CT with and 
without vasodilator was performed at a single center be-
tween October 2015 and September 2016. We compared 
the CT values in Hounsfield units of the aorta; celiac 
artery; and common, right, and left hepatic arteries in 
the arterial phase and the main trunk; right and left 
branches of the portal vein; and right, middle, and left 
hepatic veins in the portal phase with and without vaso-
dilators. The region of interest was set in each element 
of the liver vasculature. Four radiological technologists 
independently and visually compared the scores of the 
portal vein (P-score) and hepatic vein (V-score) on a 
5-point scale with and without vasodilators.
Results The CT values of arteries and veins using 
vasodilators were significantly higher than those 
without vasodilators. With and without vasodilators, the 
P-scores were 3.1 ± 1.2 and 4.0 ± 1.1 (P < 0.05) and the 
V-scores were 3.3 ± 1.4 and 4.3 ± 1.0 (P < 0.05). Only 
one patient with vasodilator use had transient hypoten-
sion and recovered immediately without medication.
Conclusion Dynamic CT with vasodilators can pro-
vides better visualization of vascular structures.
Key words abdomen; computed tomography; liver; 
vasodilator agents
Dynamic contrast-enhanced computed tomography 
(CE-CT) is useful for evaluating hepatic vascularity.1, 2 
Hepatectomy is the most effective treatment for hepa-
tocellular carcinoma and the number of laparoscopic 
approaches to liver resection has increased in recent 
years.3 Detailed knowledge of the liver vasculature 
is important to ensure a safe and successful liver sur-
gery.4, 5
Vasodilators, such, as nitroglycerin spray are 
routinely used to maximally dilate the epicardial coro-
nary arteries during coronary angiography.6 Although 
vasodilator use increases hepatic blood flow, the utility 
of dynamic CE-CT with vasodilator is unclear.7
Thus, here we aimed to examine the utility of 
dynamic CE-CT with vasodilator.
MATERIALS AND METHODS
Study population
This was a prospective case-control study of patients 
undergoing dynamic CE-CT with or without vasodilator 
use between October 2015 and September 2016 at the 
Department of Surgery of Tottori Prefectural Central 
Hospital. Patients undergoing abdominal dynamic 
CE-CT for any reason were included and those in whom 
use of vasodilators was contraindicated were excluded 
from the study. Patients who had consented to the use of 
vasodilators were randomly assigned to the intervention 
and control groups. A total of 62 patients (25 men, 37 
women) aged 38–87 years were analyzed. This study 
was approved by the ethics board of Tottori Prefectural 
Central Hospital (approval number: 16-10). Written 
informed consent was obtained from each patient.
CT protocols
Sixty patients underwent scanning at 120kV with a 
multidetector CT instrument (Aquilion ONE; Cannon 
Medical Systems, Tokyo, Japan) with breath holding 
at inspiration; the contrast dose was iodine 600 mg/kg. 
Three minutes before the initiation of contrast injection, 
sublingual nitroglycerin was administered by a nurse, 
who sprayed one puff from a spray device (0.3 mg/puff; 
Myocor spray; Toa Eiyo Company Limited, Tokyo, 
Japan). After obtaining a non-contrast CT scan, nonionic 
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contrast material [iohexol 240 mgI/mL, Omnipaque 
240 (Daiichi Sankyo Company Limited, Tokyo, Japan) 
for patients weighing < 45 kg; iopamidol 300 mgI/mL, 
Oypalomin (Fuji Pharma Company Limited, Tokyo, 
Japan) for patients weighing 45–52 kg; iopamidol 370 
mgI/mL, Iopamiron 370 (Bayer Healthcare, Osaka, 
Japan) for patients weighing 53–65 kg; and iomeprol 
350 mgI/mL, Iomeron 350 (Daiichi Sankyo Company 
Limited) for patients weighing ≥ 66 kg] was adminis-
tered at a flow rate of 3.0–5.0 mL/s using an automated 
power injector (Dual Shot GX7; Nemoto Kyorindo, 
Tokyo, Japan) following a three-phase dynamic CT 
scanning during the hepatic arterial, portal, and venous 
phases. A bolus-tracking method was used to determine 
the scanning start time in each phase after the contrast 
material injection. The anatomical level for monitor-
ing was set in the celiac artery that branched from the 
descending aorta. The trigger threshold was set at 200 
Hounsfield units (HU). Dynamic image acquisition 
consisted of three sequences: the arterial phase initiated 
7 seconds after the trigger, the portal phase acquired 
14 seconds after arterial phase, and the hepatic venous 
phase that was scanned 3 minutes after a bolus injection 
of the contrast agent.
The parameters were detector configuration (80 × 
0.5 mm) (detector collimation), slice thickness (5 mm), 
section interval (5 mm), and gantry rotation time (0.5 s), 
and 120 kV using an automatic exposure system with a 
reference standard deviation (SD) of 10.
CT values
The scanned images were processed using a ZIOSTATION 
2 workstation (Amin Company Limited, Tokyo, Japan). 
A circular region of interest of an area equivalent to 
approximately 70% of the diameter of each vascularity 
element was selected in the CT cross section and the CT 
values measured. We compared the CT values in HU of 
the arteries in the arterial phase and the portal veins and 
the hepatic veins in the portal phase with versus without 
vasodilator use. We evaluated the aorta, celiac artery, 
common hepatic artery, right hepatic artery, and left 
hepatic artery in the arterial phase as well as the main 
trunk, right and left branches of the portal vein, and 
right, middle, and left hepatic veins in the portal phase.
Visual evaluation of CT imaging
The vascular structures were visually evaluated on the 
CT cross section. All the CT images were independently 
reviewed and graded by four radiological technologists 
with 7, 9, 12, and 17 years of experience using a 5-point 
scale for visualization of the vascular structures [portal 
vein (P-score) and hepatic vein score (V-score)] (Fig. 1). 
The P-scores and V-scores were computed by calculat-
ing the average of the scores evaluated by the four 
radiological technologists. The 5-point scoring of the 
portal vein was as follows: 5 (excellent) = fifth branches 
of the portal vein are clearly visualized, sufficient 
information; 4 (good) = fifth branches of the portal vein 
are visualized, but unclear, useful information; 3 (fair) = 
fourth branches of the portal vein are clearly visualized 
but fifth branches of the portal vein are difficult to iden-
tify, acceptable information; 2 (unacceptable) = fourth 
branches of the portal vein are visualized but unclear, 
inadequate information; and 1 (poor) = third branches 
are visualized, but fourth branches of the portal vein 
are difficult to identify, poor information. The 5-point 
Fig. 1. Visual evaluation of CT imaging. All CT images were reviewed and graded by four radiologists using a 5-point scale for the 
visualization of vascular structures.
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scoring of the hepatic vein was as follows: 5 (excellent) 
= fourth branches of the hepatic vein are clearly visual-
ized, sufficient information; 4 (good) = fourth branches 
of the hepatic vein are visualized, but unclear, useful 
information; 3 (fair) = third branches of the hepatic vein 
are clearly visualized but fourth branches of the hepatic 
vein are difficult to identify, acceptable information; 2 
(unacceptable) = third branches of the hepatic vein are 
visualized but unclear, inadequate information; and 
1 (poor) = second branches are visualized, but third 
branches of the hepatic vein are difficult to identify, 
poor information.
Statistics
Continuous variables, including age and body weight, 
are expressed as mean and SD. Categorical variables, 
including sex, are expressed as numbers and percent-
ages. Summary statistics were used to compare the 
characteristics of patients undergoing dynamic CE-CT 
with versus without vasodilator use with the Mann-
Whitney U test for continuous variables and chi squared 
test for categorical variables. We used the chi squared 
tests to compare the CT values of the arteries in the 
arterial phase, the veins in the portal phase, and visual 
evaluation of CT imaging between patients undergoing 
dynamic CE-CT with versus without vasodilator use. 
Values of P < 0.05 were considered significant. We 
performed sensitivity analysis excluding patients with 
cirrhosis of the liver. All statistical analyses were per-
formed using SPSS version 25.0 (IBM, Armonk, NY). 
The patients’ data were safely stored in a locked safe, 
anonymized and analyzed on an encrypted computer 
without an internet connection.
RESULTS
The characteristics of all the patients included in this 
study are shown in Table 1. There were no significant 
differences in age, sex, or body weight between patients 
undergoing dynamic CE-CT with versus without a 
vasodilator. In the vasodilator and control groups, the 
mean ages were 63.9 ± 11.8 and 66.2 ± 13.1 (P = 0.48) 
and mean body weights were 54.1 ± 11.8 kg and 54.8 
± 12.3 kg (P = 0.84), respectively. The vasodilator and 
control groups included 52% and 59% men, respectively 
(P = 0.47). Patients under treatment with vasodilators 
had a lower evidence of liver disease than those who 
were not on vasodilators (P = 0.011). Five patients on 
vasodilators had cirrhosis of the liver, which was absent 
in those who were not using vasodilators.
Figure 2 compares the CT values in HU of the 
arteries in the arterial phase. The CT values in HU in 
patients undergoing dynamic CE-CT in the vasodilator 
and control groups were 416 ± 76.5 and 367 ± 62.7 in 
the aorta (P = 0.003), 425 ± 80.4 and 371 ± 59.4 in the 
celiac artery (P = 0.001), 416 ± 79.1 and 355 ± 60.7 in 
the common hepatic artery (P < 0.001), 376 ± 88.3 and 
259 ± 62.5 in the right hepatic artery (P < 0.001), and 
342 ± 71.3 and 241 ± 47.6 in the left hepatic artery (P < 
0.001), respectively.
Figure 3 compares the CT values of the portal 
veins and the hepatic veins in the portal phase. The CT 
values in the vasodilator and control group were 224 
± 31.8 and 206 ± 28.1 in the portal vein (P = 0.02), 217 
± 27.7 and 202 ± 30.8 in the right branch of the portal 
vein (P = 0.04), and 223 ± 29.6 and 206 ± 31.0 in the left 
branch of the portal vein (P = 0.04), respectively. In the 
vasodilator and control group, the CT values were 229 ± 
28.3 and 189 ± 26.2 in the hepatic vein (P < 0.001), and 
223 ± 38.8 and 194 ± 35.4 in the right hepatic vein (P = 
Table 1. Characteristics of all patients





Age, year 63.9 ± 11.8 66.2 ± 13.1 0.48
Male, n (%) 13 (52) 22 (59) 0.47
Body weight, kg 54.1 ± 11.8 54.8 ± 12.3 0.84
Background disease, n (%) 0.011
Hepatobiliary tract diseases 13 (52) 25 (68)
Pancreatic diseases 8 (32) 8 (22)
Gallbladder diseases 2 (8) 2 (5)
Other diseases 2 (8) 2 (5)
a Data are shown as mean ± standard deviation for quantitative data and as percentage of patients for qualitative data.
b P values were calculated using the Mann-Whitney U test for variance and the chi-square test for variables.
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Fig. 2. CT values of the arteries in the arterial phase. *P < 0.05
Fig. 3. CT values of the veins in the portal phase. *P < 0.05
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0.003), 225 ± 37.0 and 198 ± 31.8 in the middle hepatic 
vein (P = 0.002), and 215 ± 34.9 and 192 ± 30.1 in the 
left hepatic vein (P = 0.006), respectively.
Figure 4 compares the visual evaluation of CT 
imaging in the portal vein and the hepatic vein. In the 
vasodilator and control groups, the P-scores were 4.0 ± 
0.5 and 3.1 ± 0.8 (P < 0.05), respectively. The V-scores 
in the vasodilator and control groups were 4.3 ± 0.3 and 
3.3 ± 0.4 (P < 0.05), respectively.
In the vasodilator group, there was one case of 
transient hypotension that immediately recovered with-
out treatment. In the control group, no adverse events 
occurred.
In the sensitivity analysis, after excluding patients 
with cirrhosis of the liver in the control group, there 
was no significant difference in the background disease 
between patients with and without treatment with vaso-
dilators (P = 0.16). The results of the sensitivity analyses 
thus performed were consistent with the primary 
findings. The results of the aforementioned analyses are 
shown in Table 2 and Figs. 5, 6 and 7.
DISCUSSION
In this study, dynamic CE-CT with vasodilator use 
yielded statistically better visualization of the hepatic 
vascular structures than the standard dynamic CE-CT. 
These results of the present study are important because 
the utility and safety of dynamic CE-CT with vasodila-
tor use was not proven previously.
Several dynamic CE-CT protocols have been 
proposed to clarify the hepatic vascular structure.8–11 
A retrospective study showed that CT with a combined 
Fig. 4. Visual evaluation of CT imaging. *P < 0.05
Table 2. Characteristics of patients excluding those with cirrhosis of the liver in the control group





Age, year 63.9 ± 11.8 66.4 ± 13.9 0.47
Male, n (%) 13 (52) 17 (53) 0.82
Body weight, kg 54.1 ± 11.8 52.3 ± 10.7 0.62
Background disease, n (%) 0.16
Hepatobiliary tract diseases 13 (52) 20 (63)
Pancreatic diseases 8 (32) 8 (25)
Gallbladder diseases 2 (8) 2 (6)
Other diseases 2 (8) 2 (6)
a Data are shown as mean ± standard deviation for quantitative data and as percentage of patients for qualitative data.
b P values were calculated using the Mann-Whitney U test for variance and the chi-square test for variables.
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Fig. 5. CT values of the arteries in the arterial phase after excluding patients with cirrhosis of the liver. *P < 0.05
Fig. 6. CT values of the veins in the portal phase after excluding patients with cirrhosis of the liver. *P < 0.05
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technique of lower tube voltage and iterative reconstruc-
tion can provide sufficiently preoperative information 
for liver transplantation.8 A previous study showed 
that a liver CT protocol with later arterial phase, faster 
infusion rate, and weight-based dosing of intravenous 
contrast significantly improved liver enhancement 
and iodine concentrations in patients with cirrhosis.9 
Although CT values in HU of the ar teries were 
increased by changing the injection protocol, contrast 
medium amount, or device, visual evaluations of vascu-
lar construction did not improve at CT values above a 
certain level.12 We demonstrated here that the CT values 
of the arteries, and the portal veins and the hepatic veins 
in the vasodilator group were higher than those in the 
control group and that dynamic CE-CT with vasodilator 
use clearly visualized vascular structures.
In order to perform liver surgeries safely, it is 
essential to understand the complexities of the liver 
vasculature.3, 4 Particularly, in preoperative evaluation, 
it is crucial to understand the liver vasculature including 
the portal vein and hepatic vein in order to accurately 
identify the liver segments.6 It was demonstrated that 
dynamic CE-CT with the use of vasodilators provided a 
clearer visualization of the hepatic vasculature including 
the portal and hepatic veins.
Although the mechanism of clear visualization 
of vascular structures with vasodilator use remains to 
be elucidated, the previous study reported that when a 
blood vessel is expanded with a vasodilator, the periph-
eral vascular resistance is reduced and the blood volume 
is increased.13 Therefore, even if the blood concentration 
of the contrast agent remains the same, the intravascular 
volume increases, thereby improving the clinician’s 
ability to detect the vascular structure.14
A previous systematic review reported that the side 
effects of sublingual nitroglycerin administered during 
CT angiography were mild and were alleviated without 
treatment.6 The present study showed that there was 
transient hypotension in patients that was associated 
with the use of vasodilators, which but immediately im-
proved without medical intervention. Use of nitroglyc-
erin is contraindicated in patients on phosphodiesterase 
inhibitors for the treatment of erectile dysfunction or 
pulmonary hypertension.15 In this study, none of the 
patients were on phosphodiesterase inhibitors.
This study has several limitations. First, the num-
ber of cases was small, and the patients were recruited 
from a single center. In addition, patients with and 
without treatment with vasodilators are two different 
cohorts. However, there was no significant difference 
between the groups but for the presence of background 
disease. The results of the sensitivity analyses that ex-
cluded participants with cirrhosis of the liver in order to 
match the background disease were consistent with the 
primary findings. Second, it remains unclear whether 
dynamic CE-CT with vasodilator use is useful for mak-
ing the diagnosis of liver disease. However, dynamic 
CE-CT with vasodilator use enables the clear visualiza-
tion of liver vascular structures. Third, although the use 
of vasodilators may shift the timing of imaging of the 
arterial and portal phase, the CT values in HU of the he-
patic arteries and veins and the portal veins were high. 
Fourth, the weight-based dosing of the various contrast 
agents accounted for non-uniformity in vascular assess-
ment. However, the contrast agents were administered 
using a body-weight based protocol because normal 
Fig. 7. Visual evaluation of CT imaging after excluding patients with cirrhosis of the liver. *P < 0.05
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parenchymal enhancement was regulated primarily 
by the total amount of iodine injected per unit body 
weight.16 Finally, the current mainstream for enhancing 
the visualization of vascularity in CT scans include 
low tube voltage and low-dose contrast agent scan-
ning protocols that reduce radiation and iodine intake. 
However, dynamic CT with the use of vasodilators may 
be useful.17
In conclusion, dynamic CE-CT with vasodilator 
use provides better visualization of hepatic vascular 
structures than standard dynamic CE-CT. These find-
ings imply that dynamic CE-CT with vasodilator use 
may be sufficiently simple, safe, and informative for a 
preoperative CT evaluation of liver resection. Further 
investigations are needed to elucidate the utility of 
dynamic CE-CT with vasodilator use for preoperative 
CT evaluations of liver resection.
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